RNA & mRNA Proprietary Technologies

Technologies

We believe our two proprietary technologies, LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, solve major hurdles in RNA medicine development.

LUNAR®

Our first platform is a proprietary lipid-mediated nucleic acid delivery system called LUNAR®. LUNAR® is a multi-component drug delivery system that is versatile and with our library of over 250 proprietary lipids, diverse. Our preclinical studies have shown that formulations can be customized for the indication and target cell type of interest. We have also demonstrated that our formulation process is scalable and reproducible.

LUNAR® Mechanism of Delivery Video

STARR

The STARR Technology platform combines self-replicating RNA with LUNAR®, a leading nanoparticle delivery system, into a single solution to produce proteins inside the human body. The versatility of the STARR Technology enables it upon delivery into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. The self-replicating RNA-based prophylactic vaccine triggers rapid and prolonged antigen expression within host cells resulting in protective immunity against infectious pathogens. This combination of the LUNAR® and STARR technology is expected to provide lower dose requirements due to superior immune response, sustained protein expression compared to non-self-replicating RNA-based vaccines and potentially enabling to produce vaccines more quickly and simply.

COVID-19 Vaccine Using STARR mRNA Technology

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

 

News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
READ MORE
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
READ MORE
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
READ MORE
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
READ MORE
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
READ MORE
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
READ MORE
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
READ MORE
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
READ MORE
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
READ MORE
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
READ MORE
August 9, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 18, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
READ MORE
August 31, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
READ MORE
September 1, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
READ MORE
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
READ MORE
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
READ MORE
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
READ MORE